Share Price and Basic Stock Data
Last Updated: January 15, 2026, 5:46 am
| PEG Ratio | -9.30 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aster DM Healthcare Ltd operates in the Hospitals & Medical Services sector, focusing on delivering comprehensive healthcare solutions. The company’s revenue trend reflects considerable fluctuations, with sales recorded at ₹2,994 Cr for the fiscal year ending March 2023, a decline from ₹10,253 Cr in March 2022. However, revenues have shown signs of recovery, with TTM sales rising to ₹4,325 Cr. In the latest quarterly results for September 2023, sales stood at ₹929 Cr, demonstrating an upward trajectory compared to ₹841 Cr in June 2023. This trend continued into the subsequent quarter with a revenue of ₹955 Cr for December 2023, indicating a potential stabilization in revenue generation moving forward. Additionally, the overall sales growth from ₹2,871 Cr in March 2014 to ₹4,325 Cr in TTM showcases a long-term upward trend despite recent volatility, suggesting opportunities for recovery as healthcare demand rebounds post-pandemic.
Profitability and Efficiency Metrics
Aster DM Healthcare’s profitability metrics reveal a complex picture. The company reported a net profit of ₹365 Cr, yielding a P/E ratio of 85.9, which is high compared to industry standards, indicating that the stock might be overvalued based on earnings. The Operating Profit Margin (OPM) stood at 20%, reflecting efficient cost management in its operations. However, the return on equity (ROE) was recorded at 8.26%, suggesting that the company is generating a moderate return on shareholders’ investments. Notably, the Cash Conversion Cycle (CCC) was reported at -107 days, indicating that Aster DM Healthcare is effectively managing its cash flow and capital efficiency. The interest coverage ratio of 7.37x further highlights the firm’s ability to meet its interest obligations comfortably, implying a sound financial structure despite the high P/E ratio.
Balance Sheet Strength and Financial Ratios
The balance sheet of Aster DM Healthcare reflects a moderate level of financial strength. As of September 2025, total borrowings amounted to ₹2,089 Cr against reserves of ₹4,015 Cr, providing a healthy cushion for the company. The long-term debt-to-equity ratio stood at 0.14, indicating low leverage, which is favorable compared to many peers in the healthcare sector. The current ratio reported at 2.16 suggests that the company is well-positioned to cover its short-term liabilities. Furthermore, the book value per share decreased to ₹68.63 in March 2025 from ₹100.70 in the previous year, indicating a decline in net asset value. The price-to-book ratio at 7.06x indicates a premium valuation compared to the value of its underlying assets, which could raise concerns among value-oriented investors. Overall, while the balance sheet exhibits resilience, the volatility in earnings and asset valuations could pose challenges for future financial stability.
Shareholding Pattern and Investor Confidence
Aster DM Healthcare’s shareholding pattern showcases a diverse investor base, with promoters holding 40.39% of the company as of September 2025. Foreign Institutional Investors (FIIs) account for 18.72%, while Domestic Institutional Investors (DIIs) hold 26.32%. The public’s stake stands at 14.33%, reflecting a balanced distribution of ownership. Notably, promoter holdings have remained relatively stable, hovering around the 41% mark over recent quarters, which may signal confidence in the company’s long-term prospects. However, there has been a decline in FII participation from 42.49% in December 2022 to 18.72% in September 2025, which could indicate waning interest from foreign investors possibly due to the high P/E ratio and fluctuating profitability. This mixed sentiment among institutional investors could impact the stock’s market performance and overall investor confidence.
Outlook, Risks, and Final Insight
The outlook for Aster DM Healthcare appears cautiously optimistic, driven by potential recovery in revenue and efficiency metrics. Continued growth in sales, alongside strong cash flow management, positions the company favorably for the future. However, risks remain, particularly related to its high valuation metrics, such as the P/E ratio of 85.9, which may deter new investments. Additionally, the decline in FII interest raises concerns about the stock’s attractiveness to international investors. The company’s ability to navigate healthcare sector challenges, including regulatory changes and competition, will be critical. Should Aster DM Healthcare manage its operational efficiencies and stabilize profitability, it could attract renewed investor interest. Conversely, failure to address high valuation concerns and maintain growth could hinder its market performance in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.2 Cr. | 135 | 187/120 | 9.23 | 117 | 2.59 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 22.6 Cr. | 21.6 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.7 Cr. | 10.4 | 20.5/7.08 | 119 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 107 Cr. | 57.3 | 98.7/55.2 | 23.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.2 Cr. | 3.55 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,165.36 Cr | 693.20 | 90.23 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,816 | 3,192 | 807 | 841 | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 |
| Expenses | 2,498 | 2,743 | 687 | 722 | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 |
| Operating Profit | 319 | 449 | 120 | 119 | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 |
| OPM % | 11% | 14% | 15% | 14% | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% |
| Other Income | 18 | 10 | 149 | -17 | -64 | 153 | -40 | 5,120 | 35 | 9 | 5 | 29 | 28 |
| Interest | 77 | 87 | 25 | 25 | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 |
| Depreciation | 189 | 198 | 54 | 51 | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 |
| Profit before tax | 71 | 173 | 190 | 26 | -7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 |
| Tax % | 23% | 8% | 4% | 24% | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% |
| Net Profit | 54 | 159 | 183 | 20 | -15 | 209 | -2 | 5,152 | 106 | 64 | 86 | 94 | 121 |
| EPS in Rs | 0.93 | 2.79 | 3.42 | 0.10 | -0.62 | 3.59 | -0.48 | 103.00 | 1.94 | 1.14 | 1.58 | 1.65 | 2.12 |
Last Updated: January 13, 2026, 1:21 am
Below is a detailed analysis of the quarterly data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,197.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,078.00 Cr. (Jun 2025) to 1,197.00 Cr., marking an increase of 119.00 Cr..
- For Expenses, as of Sep 2025, the value is 961.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 876.00 Cr. (Jun 2025) to 961.00 Cr., marking an increase of 85.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 236.00 Cr.. The value appears strong and on an upward trend. It has increased from 202.00 Cr. (Jun 2025) to 236.00 Cr., marking an increase of 34.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Jun 2025) to 20.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Jun 2025) to 28.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 31.00 Cr..
- For Depreciation, as of Sep 2025, the value is 66.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 63.00 Cr. (Jun 2025) to 66.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 167.00 Cr.. The value appears strong and on an upward trend. It has increased from 136.00 Cr. (Jun 2025) to 167.00 Cr., marking an increase of 31.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be improving (decreasing) as expected. It has decreased from 31.00% (Jun 2025) to 27.00%, marking a decrease of 4.00%.
- For Net Profit, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 121.00 Cr., marking an increase of 27.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.12. The value appears strong and on an upward trend. It has increased from 1.65 (Jun 2025) to 2.12, marking an increase of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 2,994 | 3,699 | 4,138 | 4,325 |
| Expenses | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 2,547 | 3,124 | 3,384 | 3,520 |
| Operating Profit | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 447 | 575 | 754 | 805 |
| OPM % | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 15% | 16% | 18% | 19% |
| Other Income | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 353 | 32 | 5,169 | 71 |
| Interest | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 125 |
| Depreciation | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 256 |
| Profit before tax | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 511 | 268 | 5,542 | 496 |
| Tax % | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 7% | 21% | 2% | |
| Net Profit | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | 5,408 | 365 |
| EPS in Rs | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 | 107.66 | 6.49 |
| Dividend Payout % | 35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 4,637% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -4.23% | -97.06% | 1125.00% | 187.76% | 30.14% | -14.17% | -43.49% | 237.64% | -20.97% | -55.37% | 2450.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | -92.83% | 1222.06% | -937.24% | -157.61% | -44.31% | -29.32% | 281.13% | -258.61% | -34.40% | 2506.31% |
Aster DM Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -14% |
| 3 Years: | -26% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -7% |
| 3 Years: | -17% |
| TTM: | 82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 38% |
| 3 Years: | 38% |
| 1 Year: | 56% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 | 518 |
| Reserves | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,686 | 2,554 | 4,015 |
| Borrowings | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,758 | 2,392 | 2,089 |
| Other Liabilities | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,039 | 1,154 | 1,186 |
| Total Liabilities | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
| Fixed Assets | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | 3,920 | 4,024 |
| CWIP | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 | 293 | 401 |
| Investments | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 | 245 | 1,184 |
| Other Assets | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,620 | 2,142 | 2,199 |
| Total Assets | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
Below is a detailed analysis of the balance sheet data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 500.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,015.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,554.00 Cr. (Mar 2025) to 4,015.00 Cr., marking an increase of 1,461.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,089.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,392.00 Cr. (Mar 2025) to 2,089.00 Cr., marking a decrease of 303.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,154.00 Cr. (Mar 2025) to 1,186.00 Cr., marking an increase of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,808.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,024.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,920.00 Cr. (Mar 2025) to 4,024.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 401.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Mar 2025) to 401.00 Cr., marking an increase of 108.00 Cr..
- For Investments, as of Sep 2025, the value is 1,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 1,184.00 Cr., marking an increase of 939.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,199.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,142.00 Cr. (Mar 2025) to 2,199.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,808.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
Notably, the Reserves (4,015.00 Cr.) exceed the Borrowings (2,089.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -435.00 | 505.00 | 442.00 | 347.00 | 630.00 | -1.00 | -4.00 | -3.00 | -4.00 | 441.00 | 574.00 | 752.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 285 | 23 | 23 |
| Inventory Days | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 612 | 44 | 36 |
| Days Payable | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 1,400 | 183 | 166 |
| Cash Conversion Cycle | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -503 | -116 | -107 |
| Working Capital Days | 61 | 69 | 68 | 6 | 59 | 28 | 8 | 5 | 5 | -21 | 272 | -32 |
| ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 3% | 4% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 23,927,134 | 4.19 | 1592.23 | N/A | N/A | N/A |
| Kotak Small Cap Fund | 11,757,234 | 4.49 | 782.39 | N/A | N/A | N/A |
| Quant Small Cap Fund | 11,305,160 | 2.49 | 752.3 | 1,758,485 | 2025-12-08 07:20:44 | 542.89% |
| Nippon India Small Cap Fund | 9,522,707 | 0.92 | 633.69 | N/A | N/A | N/A |
| SBI Contra Fund | 9,199,605 | 1.23 | 612.19 | N/A | N/A | N/A |
| Kotak Midcap Fund | 6,137,365 | 0.68 | 408.41 | 5,738,292 | 2025-12-15 01:26:06 | 6.95% |
| Franklin India Small Cap Fund | 4,675,704 | 2.3 | 311.14 | 5,618,134 | 2025-12-15 01:26:06 | -16.77% |
| HDFC Childrens Fund | 3,759,174 | 2.35 | 250.15 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 3,574,000 | 1.47 | 237.83 | N/A | N/A | N/A |
| Franklin India Mid Cap Fund | 2,407,002 | 1.24 | 160.17 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 107.98 | 2.60 | 8.54 | 10.58 | 2.97 |
| Diluted EPS (Rs.) | 107.85 | 2.60 | 8.53 | 10.57 | 2.97 |
| Cash EPS (Rs.) | 113.62 | 8.87 | 25.12 | 24.96 | 15.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Revenue From Operations / Share (Rs.) | 82.85 | 74.05 | 238.89 | 206.21 | 173.19 |
| PBDIT / Share (Rs.) | 18.27 | 12.07 | 32.90 | 30.85 | 22.39 |
| PBIT / Share (Rs.) | 13.29 | 7.66 | 17.28 | 17.97 | 9.96 |
| PBT / Share (Rs.) | 9.81 | 5.46 | 10.69 | 12.80 | 4.05 |
| Net Profit / Share (Rs.) | 108.64 | 4.46 | 9.49 | 12.08 | 3.51 |
| NP After MI And SOA / Share (Rs.) | 107.66 | 2.59 | 8.51 | 10.58 | 2.97 |
| PBDIT Margin (%) | 22.05 | 16.29 | 13.77 | 14.96 | 12.92 |
| PBIT Margin (%) | 16.04 | 10.34 | 7.23 | 8.71 | 5.75 |
| PBT Margin (%) | 11.83 | 7.36 | 4.47 | 6.20 | 2.34 |
| Net Profit Margin (%) | 131.13 | 6.02 | 3.97 | 5.85 | 2.02 |
| NP After MI And SOA Margin (%) | 129.94 | 3.49 | 3.56 | 5.12 | 1.71 |
| Return on Networth / Equity (%) | 156.87 | 2.83 | 10.43 | 13.30 | 4.38 |
| Return on Capital Employeed (%) | 11.59 | 5.71 | 8.44 | 9.93 | 5.86 |
| Return On Assets (%) | 81.40 | 0.71 | 2.85 | 4.19 | 1.26 |
| Long Term Debt / Equity (X) | 0.14 | 0.09 | 0.32 | 0.37 | 0.52 |
| Total Debt / Equity (X) | 0.18 | 0.14 | 0.56 | 0.55 | 0.56 |
| Asset Turnover Ratio (%) | 0.33 | 0.22 | 0.18 | 0.14 | 0.09 |
| Current Ratio (X) | 2.16 | 1.25 | 1.06 | 1.15 | 1.14 |
| Quick Ratio (X) | 2.06 | 1.25 | 0.77 | 0.86 | 0.86 |
| Inventory Turnover Ratio (X) | 40.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 114.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 109.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -9.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 7.37 | 5.46 | 4.99 | 5.97 | 3.79 |
| Interest Coverage Ratio (Post Tax) (X) | 4.28 | 2.96 | 2.44 | 3.34 | 1.59 |
| Enterprise Value (Cr.) | 23702.29 | 21464.85 | 14334.72 | 12129.54 | 8918.86 |
| EV / Net Operating Revenue (X) | 5.73 | 5.80 | 1.20 | 1.18 | 1.04 |
| EV / EBITDA (X) | 25.97 | 35.61 | 8.72 | 7.91 | 8.02 |
| MarketCap / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| Retention Ratios (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 7.06 | 4.48 | 2.96 | 2.48 | 2.02 |
| Price / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| EarningsYield | 0.22 | 0.01 | 0.03 | 0.05 | 0.02 |
After reviewing the key financial ratios for Aster DM Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 107.98. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.98, marking an increase of 105.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 107.85. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.85, marking an increase of 105.25.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.62. This value is within the healthy range. It has increased from 8.87 (Mar 24) to 113.62, marking an increase of 104.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.85. It has increased from 74.05 (Mar 24) to 82.85, marking an increase of 8.80.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 18.27. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 18.27, marking an increase of 6.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.29. This value is within the healthy range. It has increased from 7.66 (Mar 24) to 13.29, marking an increase of 5.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 9.81, marking an increase of 4.35.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 108.64. This value is within the healthy range. It has increased from 4.46 (Mar 24) to 108.64, marking an increase of 104.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 107.66. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 107.66, marking an increase of 105.07.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 16.29 (Mar 24) to 22.05, marking an increase of 5.76.
- For PBIT Margin (%), as of Mar 25, the value is 16.04. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 16.04, marking an increase of 5.70.
- For PBT Margin (%), as of Mar 25, the value is 11.83. This value is within the healthy range. It has increased from 7.36 (Mar 24) to 11.83, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 131.13. This value exceeds the healthy maximum of 10. It has increased from 6.02 (Mar 24) to 131.13, marking an increase of 125.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 129.94. This value exceeds the healthy maximum of 20. It has increased from 3.49 (Mar 24) to 129.94, marking an increase of 126.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 156.87. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 156.87, marking an increase of 154.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.59. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 11.59, marking an increase of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 81.40. This value is within the healthy range. It has increased from 0.71 (Mar 24) to 81.40, marking an increase of 80.69.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.14, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has increased from 0.14 (Mar 24) to 0.18, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has increased from 0.22 (Mar 24) to 0.33, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 2.16. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 2.16, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.06. This value exceeds the healthy maximum of 2. It has increased from 1.25 (Mar 24) to 2.06, marking an increase of 0.81.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 40.80. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 40.80, marking an increase of 40.80.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 114.80. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 114.80, marking an increase of 114.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 109.73. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 109.73, marking an increase of 109.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -9.73. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -9.73, marking a decrease of 9.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 7.37, marking an increase of 1.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.28. This value is within the healthy range. It has increased from 2.96 (Mar 24) to 4.28, marking an increase of 1.32.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23,702.29. It has increased from 21,464.85 (Mar 24) to 23,702.29, marking an increase of 2,237.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 5.73, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 15. It has decreased from 35.61 (Mar 24) to 25.97, marking a decrease of 9.64.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For Retention Ratios (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Price / BV (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 4.48 (Mar 24) to 7.06, marking an increase of 2.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For EarningsYield, as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.22, marking an increase of 0.21.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aster DM Healthcare Ltd:
- Net Profit Margin: 131.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.59% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 156.87% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.28
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 85.8 (Industry average Stock P/E: 90.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 131.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Bengaluru Kerala 560027 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Azad Moopen | Founder Chairman & Mng. Director |
| Ms. Alisha Moopen | Deputy Managing Director |
| Mr. Daniel Robert Mintz | Non Executive Director |
| Mr. T J Wilson | Non Executive Director |
| Mr. Shamsudheen Bin Mohideen Mammu Haji | Non Executive Director |
| Dr. Zeba Azad Moopen | Non Executive Director |
| Mr. Anoop Moopen | Non Executive Director |
| Ms. Purana Housdurgamvijaya Deepti | Independent Director |
| Mr. Chenayappillil John George | Independent Director |
| Mr. Maniedath Madhavan Nambiar | Independent Director |
| Mr. Sunil Theckath Vasudevan | Independent Director |
| Dr. James Mathew | Independent Director |
| Mr. Emmanuel David Gootam | Independent Director |
FAQ
What is the intrinsic value of Aster DM Healthcare Ltd?
Aster DM Healthcare Ltd's intrinsic value (as of 15 January 2026) is ₹500.16 which is 17.74% lower the current market price of ₹608.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹31,504 Cr. market cap, FY2025-2026 high/low of ₹732/386, reserves of ₹4,015 Cr, and liabilities of ₹7,808 Cr.
What is the Market Cap of Aster DM Healthcare Ltd?
The Market Cap of Aster DM Healthcare Ltd is 31,504 Cr..
What is the current Stock Price of Aster DM Healthcare Ltd as on 15 January 2026?
The current stock price of Aster DM Healthcare Ltd as on 15 January 2026 is ₹608.
What is the High / Low of Aster DM Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aster DM Healthcare Ltd stocks is ₹732/386.
What is the Stock P/E of Aster DM Healthcare Ltd?
The Stock P/E of Aster DM Healthcare Ltd is 85.8.
What is the Book Value of Aster DM Healthcare Ltd?
The Book Value of Aster DM Healthcare Ltd is 87.5.
What is the Dividend Yield of Aster DM Healthcare Ltd?
The Dividend Yield of Aster DM Healthcare Ltd is 0.82 %.
What is the ROCE of Aster DM Healthcare Ltd?
The ROCE of Aster DM Healthcare Ltd is 10.7 %.
What is the ROE of Aster DM Healthcare Ltd?
The ROE of Aster DM Healthcare Ltd is 8.26 %.
What is the Face Value of Aster DM Healthcare Ltd?
The Face Value of Aster DM Healthcare Ltd is 10.0.